Eton Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Eton Pharmaceuticals can proceed with a lawsuit against Extreme V, alleging trademark infringement and false advertising. The company claims Extreme V marketed a dietary supplement as a treatment for Wilson disease. A Michigan federal judge denied Extreme V's motion to dismiss the case.
Krempa David (Chief Business Officer) sold 25,000 shares of Eton Pharmaceuticals, Inc. (ETON) at $65.07 ($1.63M total) on 2026-08-24.
Eton Pharmaceuticals (ETON) reported Q2 earnings with a return to profitability and raised full-year 2026 revenue guidance to at least $145M. The stock has seen significant gains, with a 30-day return of 49.03% and a 1-year return of 266.88%. Analysts' consensus price target is $45.67, suggesting a 39% overvaluation, but a DCF model estimates a fair value of $285.41. Risks include pricing pressure and regulatory setbacks.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ETON (Eton Pharmaceuticals, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent ETON coverage spans earnings, insider activity and market movers.
In the last 30 days, ETON insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($7.7M). The most active reporter was BRYNJELSEN SEAN, President & CEO, with 4 filings.
Potential liability and reputational risk for Eton may pressure its stock.
The insider sale may signal reduced confidence or a liquidity need, potentially pressuring the stock short-term.
Positive earnings surprise and higher guidance may drive short‑term upside.
Strong earnings beat and upgraded guidance suggest upside potential, but increased R&D spend and margin pressure from new product launches may temper gains.
Significant insider sell may signal reduced confidence or liquidity need, potentially pressuring the stock.
alphai scores every news story that mentions ETON with an AI model for sentiment and relevance, and aggregates insider trades from Eton Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eton Pharmaceuticals can proceed with a lawsuit against Extreme V, alleging trademark infringement and false advertising. The company claims Extreme V marketed a dietary supplement as a treatment for Wilson disease. A Michigan federal judge denied Extreme V's motion to dismiss the case.
1 min readKrempa David (Chief Business Officer) sold 25,000 shares of Eton Pharmaceuticals, Inc. (ETON) at $65.07 ($1.63M total) on 2026-08-24.
1 min readEton Pharmaceuticals (ETON) reported Q2 earnings with a return to profitability and raised full-year 2026 revenue guidance to at least $145M. The stock has seen significant gains, with a 30-day return of 49.03% and a 1-year return of 266.88%. Analysts' consensus price target is $45.67, suggesting a 39% overvaluation, but a DCF model estimates a fair value of $285.41. Risks include pricing pressure and regulatory setbacks.
2 min readEton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% YoY, driven by HEMANGEOL relaunch and pediatric endocrinology growth. FY 2026 revenue guidance raised to over $145M. Adjusted EBITDA was $16.2M (43% margin). ASN-001 licensing and study costs total $7M. Non-GAAP net income was $14.3M ($0.43/diluted share).
2 min readEton Pharmaceuticals (ETON) CEO Sean Brynjelsen sold $6.08m in shares at prices between $60.17 and $62.65 in mid-August. The stock is near its 52-week high, up 262% over the past year. InvestingPro notes the stock may be overvalued. Eton reported strong Q2 2026 earnings, beating estimates with $0.43 EPS and $37.6m revenue, driven by rare-disease portfolio growth.
1 min readBRYNJELSEN SEAN (President & CEO) sold 100,000 shares of Eton Pharmaceuticals, Inc. (ETON) at an average of $60.88 ($60.17–$62.65, $6.09M total) across 4 trades over 2026-08-19 to 2026-08-20.
1 min readAnalysts upgraded Eton Pharmaceuticals' (ETON) 2026 revenue forecast to $150M (up 42% YoY) and EPS to $1.09 (up 145%). The price target increased 30% to $71.00. The stock gained 51% in the last 7 days. Analysts expect growth to accelerate, outpacing industry averages.
2 min readThe Dow Jones Industrial Average fell about 123 points, or 0.23%, to 53,609.60 at the open and closed Friday down about 108 points to 53,732.41, extending a weekly loss to 0.6%. The S&P 500 rose 0.4% to 7,785.76 and the Nasdaq gained 0.1% to 26,729.16. Earnings drove stock moves: Eton Pharmaceuticals (ETON) rose over 44% on results and FY26 guidance, while KinderCare (KLC) fell about 46% after weaker results and lower FY26 guidance. Investors also digested weaker consumer sentiment and retail sa
6 min readBiotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.
4 min readEton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% year over year, driven by HEMANGEOL sales. Net income was $11.6M, or $0.35/share, versus a net loss in Q2 2025. The company raised 2026 revenue guidance to over $145M and expects adjusted EBITDA margin of at least 35%.
6 min read
